Help us improve our information
We need your help to improve our information to better support people with Crohn’s and Colitis. Fill in our short survey to let us know what we're doing well and how we can better meet your needs.
Last full review: October 2022
Next review date: October 2025
This information is for people with Crohn’s or Colitis who are on ustekinumab treatment or who are thinking about starting it. Our information can help you decide if this treatment is right for you. It looks at:
This information is about ustekinumab in general. It should not replace advice from your IBD team.
We need your help to improve our information to better support people with Crohn’s and Colitis. Fill in our short survey to let us know what we're doing well and how we can better meet your needs.
Ustekinumab is known by several brand names, including:
Stelara was the first brand of ustekinumab. Pyzchiva, Steqeyma, Uzprovo and Wezenla work in the same way but are known as ‘biosimilars’. This means they are very similar to Stelara and have the same treatment effects. But there are some slight differences, such as different ingredients and length of shelf life. They also vary in which of the conditions they can be used to treat. Some can only be used to treat Crohn’s while others can be used to treat Crohn’s or Colitis. The brand that you are given won’t affect your treatment, but you may want to ask your healthcare professional which brand you take. For more about biosimilars see our information on biologic medicines.
Ustekinumab is an antibody that’s made by living cells in a lab. It is a type of biologic medicine.
Antibodies are proteins that recognise and stick to specific targets. Ustekinumab sticks to two different targets: chemical messengers called IL-12 and IL-23. Your immune system naturally makes these chemical messengers to help you fight infections. But they can also cause inflammation. Scientists think they are important in the inflammation that happens in your gut when you have Crohn’s or Colitis.
Ustekinumab works by blocking the effects of IL-12 and IL-23. This reduces inflammation. But, like many other treatments for Crohn’s and Colitis, it also alters your immune system.
Ustekinumab is used to treat adults who have moderate to severely active Crohn’s or Colitis. It aims to get your Crohn’s or Colitis under control and keep it under control.
Ustekinumab can only be prescribed by a specialist in a hospital. Your IBD team might suggest it for you if you have Crohn’s or Colitis and:
Standard treatments include aminosalicylates, oral steroids or immunosuppressants like azathioprine, mercaptopurine or methotrexate. Biologic medicines include infliximab, adalimumab, golimumab and vedolizumab.
If you have Ulcerative Colitis, you can only have ustekinumab on the NHS if adalimumab, infliximab or golimumab have not worked for you or are not suitable for you.
There are lots of things to think about when you start a new treatment. Your IBD team will discuss your options with you. They might give you a choice of different treatments. You should consider the potential benefits, possible risks, and the goals of your treatment together. Things to consider include:
Our Appointment guide includes a list of questions you might want to ask. It can help you focus on what matters most to you. We also have information on other medicines or surgery for Crohn’s or Colitis that you might find helpful.
Use this tool to understand more about potential treatment options that suit your needs. The tool is designed to help you:
Ustekinumab can be effective at improving symptoms and keeping your Crohn’s or Colitis under control. But it does not work for everyone.
Find out more about how we talk about the effectiveness of medicines.
At first, the aim of ustekinumab treatment is to reduce the inflammation in your gut and get your Crohn’s or Colitis under control. This is called induction treatment. Once your Crohn’s or Colitis is under control, treatment aims to keep it under control. This is called maintenance treatment.
Some clinical trials look at how well a medicine works as induction treatment. Some look at how well it works as maintenance treatment. Some look at how well it works for both. We do not always have the same information for different medicines or different conditions.
For Crohn’s Disease, we have information about how well ustekinumab works for induction treatment and maintenance treatment separately.
The table below shows how well treatment with ustekinumab gets Crohn’s under control after 6 weeks of treatment.
More people had their Crohn’s under control after taking ustekinumab compared with people who had not been taking ustekinumab (placebo). But many people did not respond to ustekinumab. Some people who did not respond after 6 weeks might have responded with more doses of ustekinumab. But they might not.
Another analysis looked at how well ustekinumab treatment keeps Crohn’s under control. In this analysis, people who responded to ustekinumab induction treatment either carried on taking ustekinumab or switched to dummy treatment (placebo). Some of these people had already been treated with other biologic medicines. Some had not.
The table below shows results after 44 weeks of maintenance treatment.
More people had their Crohn’s under control after ustekinumab than people who had not been taking ustekinumab (placebo). But not everyone responded to ustekinumab. Evidence from using ustekinumab in the real world, outside clinical trials, has shown similar results.
A long-term trial followed-up people treated with ustekinumab for 5 years. Overall, 45 to 55 in 100 people who responded to treatment with ustekinumab were still in remission after 5 years.
Some small trials suggest ustekinumab might be effective at treating perianal fistulas in people with Crohn’s. A perianal fistula is a narrow tunnel that can develop between your back passage and the skin near your bum.
Most of the trials that looked at how well ustekinumab works in people with perianal fistulas were small and did not include a placebo group. It’s difficult to know for sure how effective it is, but it could be helpful for some people.
We have separate information on Living with a fistula.
For Ulcerative Colitis, we have information about how well ustekinumab works for induction treatment and maintenance treatment separately.
The table below shows how well ustekinumab gets Ulcerative Colitis under control after 8 weeks of treatment.
More people had their Colitis under control after taking ustekinumab for 8 weeks compared with people who had not been taking ustekinumab (placebo). But not everyone responds to ustekinumab. Some people might respond after more than 8 weeks.
People who already had their Ulcerative Colitis under control after 8 weeks either carried on taking ustekinumab or switched to placebo. The table below shows how well ustekinumab keeps Ulcerative Colitis under control after another 44 weeks of treatment:
More people had their Colitis under control after taking ustekinumab than people who had not been taking ustekinumab (placebo). But not everyone responded to ustekinumab.
A longer-term trial followed-up people treated with ustekinumab for 2 years. Overall, 65 to 68 in 100 people who responded to treatment with ustekinumab were still in remission after 2 years.
Everyone responds differently to a new medicine. You might start to feel better as early as 3 weeks after starting ustekinumab. But most people who respond to ustekinumab start feeling better within 6 to 8 weeks. In some people it could take up to 16 weeks. Some people might not respond at all.
If your Crohn’s or Colitis has not improved within 16 weeks, your IBD team might suggest that you have ustekinumab every 8 weeks instead of every 12 weeks. If you still do not respond after another 16 weeks, they might suggest stopping ustekinumab and trying a different treatment option.
You cannot take ustekinumab by mouth because it is broken down by the gut, which stops it working. Instead, you have it through a drip for your first dose, and then as an injection under your skin.
Ustekinumab injections are available as a pre-filled syringe or a pre-filled injection pen.
You have your ustekinumab injections delivered directly to your home. They come in a box containing either one pre-filled syringe or one pre-filled injection pen. Each syringe or pen contains one dose of medicine. Ustekinumab is free for people who are entitled to NHS care.
Ustekinumab pre-filled syringe
You must keep ustekinumab in the fridge at a temperature of 2°C to 8°C. Do not freeze it. If you need to, you can keep it out of the fridge at room temperature (up to 30°C) for up to 30 days. If you do this, keep it in its box to protect it from light. Write the date you took it out of the fridge on the box.
Once ustekinumab has been out of the fridge at room temperature, do not put it back in the fridge.
Ustekinumab pre-filled pen
You must keep ustekinumab in the fridge at a temperature of 2°C to 8°C. Do not freeze it. If you need to, you can keep it out of the fridge at room temperature (up to 30°C) for up to 30 days. If you do this, keep it in its box to protect it from light. Write the date you took it out of the fridge on the box.
Once ustekinumab has been out of the fridge at room temperature, do not put it back in the fridge.
Do not shake the pre-filled pen as this may damage the medicine.
Get rid of any doses that are past their expiry date or have been out of the fridge for more than 30 days. Your pharmacist can tell you how to dispose of them.
Your doctor or nurse will teach you how to inject yourself with ustekinumab. The Patient Information Leaflet also contains detailed instructions on what to do. This is in the box. It is sometimes called a Package Leaflet. You can also get it online: Patient Information Leaflet for ustekinumab pre-filled syringe or Patient Information Leaflet for ustekinumab pre-filled pen.
One of the most common side effects of ustekinumab is pain and redness at the injection site. These tips can help:
Your first dose of ustekinumab depends on how much you weigh.
This is the dose that you have through a drip in hospital.
After the first dose, all the rest of your doses are 90mg. The dose is the same however much you weigh. You have these as an injection under your skin.
If you respond to ustekinumab and have no serious side effects, you usually carry on taking it for at least a year. Every year, your IBD team should assess you to check whether continuing ustekinumab is the best option. If you, or your IBD team, feel that it is no longer right for you, you should discuss other treatment options together.
There are a few reasons why you or your IBD team might think about stopping or changing your treatment:
Do not stop taking ustekinumab without discussing it with your IBD team.
If ustekinumab is no longer the best treatment for you, your IBD team should discuss other treatment options with you. You should consider the potential benefits, possible risks, and the goals of your treatment together.
It is safe to take ustekinumab alongside steroids or immunosuppressants like azathioprine, mercaptopurine or methotrexate. Your IBD team will talk to you about whether you need to take other medicines for your Crohn’s or Colitis.
If you are on steroids when you start ustekinumab, you might be able to gradually stop them if you respond well to treatment. Your IBD team will advise you about this.
Do not stop steroid treatment without talking to your IBD team.
Having treatment that alters your immune system makes you more likely to get infections. And it can sometimes cause any inactive viruses you have in your body to become active again. Before you start ustekinumab, your IBD team will do thorough checks to make sure it’s suitable for you. They are likely to:
If you have an infection, you might need to delay starting ustekinumab until it’s been treated.
You should not take ustekinumab if you have active TB. If you have underlying, inactive TB, it needs to be treated before you start ustekinumab.
Tell your IBD team if:
After you start ustekinumab, you should have regular checks to see how well it is working. Your IBD team will ask about your symptoms, any side effects you’re getting, and how you’re managing with the injections. They will also check for any signs of infection. They may check whether you have any factors that put you at higher risk of having a heart attack or stroke. You might have blood tests and faecal calprotectin testing. Your IBD team will tell you what checks you need and how often.
Once you’ve got used to ustekinumab, you should have a check-up every year. This is to check if you are still responding to ustekinumab or whether you need to change the dose or stop treatment.
In theory, there is a risk that ustekinumab might slightly increase your risk of developing some cancers. This is because of the way ustekinumab affects your immune system.
Clinical trials of ustekinumab found that people taking ustekinumab had a similar rate of cancer to the general population. But some cases of cancer have been seen in people taking ustekinumab for psoriasis. This is being checked in larger, long-term studies.
If you have cancer, or you’ve had cancer in the past, ustekinumab might not be the right choice for you. Your doctor should carry out regular skin examinations to check for any signs of skin cancer.
To be safe, it’s a good idea to:
Very rarely, people taking ustekinumab may develop a condition similar to lupus. Contact your GP, IBD team or NHS 111 straightaway if you get a skin rash, especially if it’s on a part of your skin that’s exposed to the sun or you also have joint pains. If you develop a condition related to lupus, your IBD team might advise you to stop taking ustekinumab. Tell your IBD team if you have had lupus in the past before starting ustekinumab.
All medicines can have side effects, but not everyone gets them. Some side effects can happen right away, others might happen later.
Some side effects are mild and may go away on their own or after you stop taking ustekinumab. Others may be more serious and could need treatment. Some side effects might mean that the ustekinumab is not right for you.
In clinical trials, the risk of getting side effects was similar in people taking ustekinumab to people not taking ustekinumab (the placebo group).
Speak to your IBD team if you get any side effects.
We also encourage you to report any side effects to the Medicines and Healthcare Products Regulatory Agency (MHRA). You can do this through the Yellow Card scheme online or by downloading the MHRA Yellow Card app. This helps collect important safety information about medicines.
Some people might get serious side effects that need urgent treatment. These do not happen often, but it is important to know what to look out for.
Up to 1 in every 100 people taking ustekinumab might have an allergic reaction. But serious allergic reactions are rare. Less than 1 in every 1000 people taking ustekinumab get them.
Contact NHS 111 straight away if you think you are having an allergic reaction.
Signs to look out for include:
After the allergic reaction has been treated, contact your IBD team to let them know what has happened.
Ustekinumab alters your immune system. This means your body might not fight off infections as well as other people. You might get more infections than you used to. Or they might last longer or be more serious than usual.
Up to 1 in every 10 people taking ustekinumab might get a cold, a cough or a throat or sinus infection. Up to 1 in every 100 people taking ustekinumab might get more serious infections, like chest infections, skin infections or shingles.
Contact your GP or NHS 111 straight away if you think you have an infection.
Signs to look out for include:
If you have an infection, you may need urgent treatment. Your IBD team might advise you to stop taking ustekinumab until you are better.
To reduce your risk of getting an infection, try to avoid close contact with people who have infections. It’s sensible to wash your hands often, especially before meals and after using the toilet. And take care to store and prepare food safely.
Here, we list the most common side effects of ustekinumab. These might affect up to 1 in every 10 people taking ustekinumab.
This is not a full list of side effects. There is information about less common side effects of ustekinumab in the Patient Information Leaflet. This is also called a Package Leaflet. It should be in the box with your medicine. You can also get it online: Patient Information Leaflet for ustekinumab pre-filled syringe or Patient Information Leaflet for ustekinumab pre-filled pen.
There is no evidence that ustekinumab interacts with other medicines. But it’s always best to check first.
Speak to your doctor or pharmacist if you’re taking, or plan to take, any other medicines. This includes medicines you buy from a pharmacy or supermarket, as well as herbal, complementary, or alternative medicines.
Live vaccines are made using weakened versions of living viruses or bacteria. If you have a lowered immune system, there is a possibility they might cause infections. Live vaccines used in the UK include:
If someone you live with is due to have a live vaccine, ask your IBD team if you need to take any precautions.
It is safe to have non-live vaccines when you are on ustekinumab.
Everyone with Crohn’s or Colitis taking a biologic medicine should be invited to have the flu jab every year. You may be advised to have the pneumococcal vaccine. You are also eligible for all doses of COVID-19 vaccination. These are not live vaccines and they are safe to have when you are taking ustekinumab.
We have not found any clinical trials that looked at the best time to have vaccinations in relation to your ustekinumab dose. But in general, people taking ustekinumab for Crohn’s or Colitis respond well to vaccination.
Ustekinumab did not have harmful effects on pregnancy during studies on animals. Studies in humans have not found any sign that ustekinumab causes problems during pregnancy or to babies exposed during pregnancy. But the number of people who have taken ustekinumab while they were pregnant is fairly small.
Drug manufacturers advise you to use effective contraception while taking ustekinumab and for at least 15 weeks after you stop treatment. This is to prevent pregnancy.
Experts agree that taking ustekinumab while you’re pregnant is probably a low risk. You and your IBD team should discuss whether the benefits of taking it outweigh any potential risks to you and your baby.
In studies on animals, ustekinumab had no effect on male fertility. Ustekinumab does not pass into semen, or affect semen quality, in humans.
We have separate information about Reproductive health and fertility, Pregnancy and breastfeeding.
Ustekinumab passes into breast milk in very low levels. You can’t take biologic medicines like ustekinumab by mouth because they are broken down and destroyed by your gut. Ustekinumab in breastmilk is likely to be broken down in your baby’s gut. So very little will be absorbed by your baby.
There is very little information on taking ustekinumab during breastfeeding. But experts agree that it is unlikely to be harmful to your baby.
Tell your IBD team if you are thinking about breastfeeding while taking ustekinumab. They can help you weigh up the benefits of breastfeeding against any possible risks.
We have separate information about Pregnancy and breastfeeding.
There is no evidence that drinking alcohol affects the way your body deals with ustekinumab. But to keep the health risks from alcohol low, it is best to keep to recommended limits.
Taking medicines and managing side effects can be difficult – we understand and we’re here to help. Our Helpline can answer general questions about treatment options and can help you find support from others with the conditions.
Your IBD team are also there to help. You can talk to them about your dosage, how they’ll be monitoring you and what other options there might be. You should also get in touch with your IBD team if you have any new symptoms or side effects.
It can take time to find the medicine that’s right for you. Don’t be afraid to ask questions and seek out extra support when you need it.
This information is general and does not replace specific advice from your health professional. Talk to your GP or IBD team for information that’s specific to you.
We follow strict processes to make sure our information is based on up-to-date evidence and easy to understand.
Please email us at evidence@crohnsandcolitis.org.uk if:
You can also write to us at Crohn’s & Colitis UK, 1 Bishop Square, Hatfield, AL10 9NE, or contact us through our Helpline: 0300 222 5700
We know it can be difficult to live with, or support someone living with these conditions. But you’re not alone. We provide up-to-date, evidence-based information and can support you to live well with Crohn’s or Colitis.
Our helpline team can help by:
Providing information about Crohn’s and Colitis.
Listening and talking through your situation.
Helping you to find support from others in the Crohn’s and Colitis community.
Providing details of other specialist organisations.
Please be aware we’re not medically or legally trained. We cannot provide detailed financial or benefits advice or specialist emotional support.
Please contact us via telephone, email or LiveChat - 9am to 5pm, Monday to Friday (except English bank holidays).
If you need specific medical advice about your condition, your GP or IBD team will be best placed to help.
Would you like to save the changes made to this page?
Your details were successfully saved.